CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0671 (clinicaltrials.gov NCT No: NCT01253707)
Title:A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
Principal Investigator:David S. Hong
Treatment Agent:AMG 337
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of AMG 337 that can be given to patients with advanced cancer. The safety of
AMG 337 will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Gastrointestinal; Kidney; Liver; Pancreas
Phase of Study:Phase I
Treatment Agents:AMG 337
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Amgen Inc.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:David S. Hong
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults